Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (>=N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival

Tarih
1996
Yazar
WİERZBİCKİ, R
Mansouri, A
Oliveira, J
Raposo, J
KOSMİDİS, PA
PRASAD, U
GANESAN, S
EL GUEDDARİ, B
BACHOUCHİ, M
LİANES, P
PENA, C
ESCHWEGE, F
RAHAL, M
DOSEN, .
MERSİC, Z
KRAJİNA, Z
ARMAND, JP
BOUHRİS, J
BENHAMOU, E
DUCOURTİEUX, M
AZLI, N
FANDİ, A
TAAMMA, A
BOSQ, J
KLİJANİENKO, J
SİGAL, R
HONG, WK
VOKES, EE
CLARK, JR
LE FLOCH, O
BERNİER, J
ALTUN, Musa
ONAT, Haluk
Cvitkovic, E
TubianaMathieu, M
Fountzilas, G
Üst veri
Tüm öğe kaydını göster
Özet
Purpose: Our Phase II trial using bleomycin, epirubicin, and cisplatin (BEG) protocol in the treatment of locoregionally advanced undifferentiated nasopharyngeal carcinoma (UCNT) patients has shown encouraging results with high objective response, disease-free survival, and overall survival rates. To establish the value of this BEC regimen as neoadjuvant chemotherapy, we initiated in 1989 a large international Phase III trial. It compares three cycles of EEC followed by radiotherapy to radiotherapy alone.
Bağlantı
http://hdl.handle.net/20.500.12627/93685
https://doi.org/10.1016/s0360-3016(96)80007-1
Koleksiyonlar